Home › Research › What the research found › Every row
Every row of the evidence table
One row per finding: what was tested, which way the result went, and how the study was built. The answer by area, and where the studies disagree, are on the main page.
Every row
Filter
Showing 5 of 382 rows for Rare protective or risk variant (APOE3 Christchurch, APOE R145C, RELN, FN1). One row per study per exposure: a study that tested two different things appears twice, once for each.
Scroll the table sideways to see every column.
| Exposure | Question | Direction | Outcome measured | Design | People | Effect size, as the source reported it | Source |
|---|---|---|---|---|---|---|---|
| Rare protective or risk variant (APOE3 Christchurch, APOE R145C, RELN, FN1) Genes (not modifiable) | Prevention |
Benefit
whyDirection is for one copy of the APOE3 Christchurch variant: median onset of cognitive impairment at 52 versus 47 years in matched PSEN1 E280A carriers without it, with preserved brain metabolism and fewer vascular amyloid features in the few imaged or autopsied. Not modifiable. |
Age at onset of cognitive impairment in PSEN1 E280A carriers | cohort study | 1,077 | the median age at the onset of cognitive impairment was 52 years (95% confidence interval [CI], 51 to 58), in contrast to a matched group of PSEN1 E280A carriers without the APOE3 Ch variant, among whom the median age at the onset was 47 years (95% CI, 47 to 49) |
New England Journal of Medicine
2024 ✓ Peer-reviewed PMID 38899694 |
| Rare protective or risk variant (APOE3 Christchurch, APOE R145C, RELN, FN1) Genes (not modifiable) | Prevention |
Benefit
whyDirection is for carrying the rare FN1 variant rs140926439 in APOE ε4 homozygotes: odds of AD 0.29 and onset delayed 3.37 years in the 7185-person validation cohort, with zebrafish work suggesting fibronectin loss of function reduces gliosis. Not modifiable. |
Alzheimer's disease case status and age at onset among APOE ε4 homozygotes | case-control study | 7,185 | rs140926439 variant in FN1 was protective of AD (OR = 0.29; 95% CI [0.11, 0.78], P = 0.014) and delayed age at onset of disease by 3.37 years (95% CI [0.42, 6.32], P = 0.025) |
Acta Neuropathologica
2024 ✓ Peer-reviewed PMID 38598053 |
| Rare protective or risk variant (APOE3 Christchurch, APOE R145C, RELN, FN1) Genes (not modifiable) | Prevention |
Harm
whyDirection is for carrying the African ancestry-specific APOE R145C variant with an ε3/ε4 genotype: three-fold higher odds of AD and onset about six years earlier in the discovery stage, replicated in stage 2 and concordant in stage 3. Not modifiable. |
Alzheimer's disease case status and age at onset among APOE ε3/ε4 carriers of African ancestry | case-control study | 31,929 | R145C was associated with an increased risk of AD (odds ratio [OR], 3.01; 95% CI, 1.87-4.85; P = 6.0 × 10-6) and was associated with a reported younger age at AD onset (β, -5.87 years; 95% CI, -8.35 to -3.4 years; P = 3.4 × 10-6) |
JAMA
2023 ✓ Peer-reviewed PMID 36809323 |
| Rare protective or risk variant (APOE3 Christchurch, APOE R145C, RELN, FN1) Genes (not modifiable) | Prevention |
No direction reported
whyA single case report: one man with the PSEN1 E280A mutation stayed cognitively intact until 67 despite very heavy amyloid, and carried a gain-of-function RELN variant. With one case and no comparison group beyond the earlier Christchurch case, no direction can be recorded. |
Cognitive status and amyloid/tau burden in one PSEN1 E280A carrier heterozygous for RELN-COLBOS | None | not stated | not established — case report; the abstract reports no effect estimate. |
Nature Medicine
2023 ✓ Peer-reviewed PMID 37188781 |
| Rare protective or risk variant (APOE3 Christchurch, APOE R145C, RELN, FN1) Genes (not modifiable) | Prevention |
No direction reported
whyAmong 37 heterozygous carriers (ages 56.6-82.1) none had developed AD or MCI by the March 2022 data freeze and apolipoprotein B was lower than in non-carriers, but the authors say continued follow-up is necessary and no homozygotes were found, so protection could not be tested. No incidence comparison is reported, so no direction is recorded. |
Alzheimer's disease or MCI diagnoses and blood lipid biomarkers in heterozygous APOE Christchurch carriers | cohort study | 455,306 | not established — research letter with no pubmed abstract; the full text at pmc10685495 reports carrier counts and p-values (apob p = 0.004; p = 0.036… |
Molecular Neurodegeneration
2023 ✓ Peer-reviewed PMID 38017580 |
Last updated